OBT’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more

87 Followers on Owler
87 Followers on Owler
87 Followers on Owler
87 Followers on Owler

OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more

Christian Rohlff's photo - Founder & CEO of OBT

Founder & CEO

Christian Rohlff

CEO Approval Rating

86/100

Founded:

2003

Status:

PrivateIndependent Company

Est. Annual Revenue
Est. Employees

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

CytomX is OBT's #1 competitor. CytomX is a Public company that was founded in 2008 in South San Francisco, California. CytomX is in the Biotechnology industry. Compared to OBT, CytomX has 128 more employees.

ADC Therapeutics is seen as one of OBT's biggest rivals. ADC Therapeutics was founded in Epalinges, Vaud} in 2011. ADC Therapeutics is in the Biotechnology field. Compared to OBT, ADC Therapeutics generates $2.2M less revenue.

ADC BIO is one of OBT's top competitors. ADC BIO is headquartered in Chester, England, and was founded in 2010. ADC BIO competes in the Biotechnology industry. ADC BIO generates 88% the revenue of OBT.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 30 a good estimate for OBT's Employee count?

Acquisitions

No recent acquisitions found related to OBT

OBT Funding History

$10M$20M$22.6M

Since OBT was founded in 2003, it has participated in 3 rounds of funding. In total OBT has raised $22.6M. OBT's last funding round was on Aug 2018 for a total of $2.6M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Aug 2018
$2.6M
Debt
Jan 2017
$10M
Debt
Jul 2015
$10M

Silicon Valley Bank

Since OBT was founded in 2003, it has participated in 3 rounds of funding. In total OBT has raised $22.6M. OBT's last funding round was on Aug 2018 for a total of $2.6M

Investments

No recent investments found related to OBT

OBT News

December 12, 2018BioPortfolio

WuXi Biologics Announces $450 Million Bispecific Deal with Oxford BioTherapeutics

WuXi Biologics formed a $450 million partnership with England's Oxford BioTherapeutics to develop fiv... See more »
December 11, 2018PipelineReview

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody Platform for Five Bispecific Antibody Programs for up to $450 Million

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering... See more »
December 11, 2018FirstWord Pharma

Oxford BioTherapeutics, WuXi Bioligics ink deal to develop bispecific antibodies for cancer treatment

Oxford BioTherapeutics entered an expanded deal with WuXi Biologics potentially worth more than $450 ... See more »
August 20, 2018BioPortfolio

Oxford BioTherapeutics Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 11072018 Prices from USD $250

SummaryOxford BioTherapeutics Ltd OBT is a clinical stage oncology company that develops antibody dru... See more »
August 3, 2018privateequitywire

Calculus Capital invests GBP2 million in Oxford BioTherapeutics

Calculus Capital, an Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist, h... See more »
March 22, 2018BioPortfolio

Oxford BioTherapeutics Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 14032018 Prices from USD $250

SummaryOxford BioTherapeutics Ltd Oxford BioTherapeutics is a biotechnology company that develops ant... See more »
March 1, 2018FierceBiotech

Oxford BioTherapeutics raids Celgene for CMO as I-O trial plan takes shape

Oxford BioTherapeutics has lured Abderrahim Fandi, M.D., Ph.D., away from Celgene to serve as its CMO... See more »

OBT Press Releases

September 12, 2017PR Newswire

New Opportunities for Menarini and OBT

POMEZIA, Italy and OXFORD, England, September 12, 2017 /PRNewswire/ -- Oncology Alliance between Mena... See more »
June 25, 2015PR NEWSWIRE

Invenra and Oxford BioTherapeutics Enter Collaboration to Discover Novel Therapeutic Antibodies Targeting Cancer

MADISON, Wis. and OXFORD, England, June 25, 2015 /PRNewswire/ -- Invenra, Inc., a pre-clinical stage ... See more »
June 18, 2015PRSYNC

Oxford BioTherapeutics Ltd - Product Pipeline Review - 2014

Oxford BioTherapeutics Ltd - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Oxford ... See more »
May 26, 2015PR-INSIDE.COM

Oxford BioTherapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

(PR-inside.com) Oxford BioTherapeutics Ltd (Oxford BioTherapeutics) is a biotechnology company. It fo... See more »
February 23, 2015PR NEWSWIRE

Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston

OXFORD, England and SAN JOSE, California, February 23, 2015 /PRNewswire/ -- Oxford BioTherapeutics, a... See more »
November 25, 2014PR NEWSWIRE

$1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics Initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukemia

OXFORD, England and BERLIN, November 25, 2014 /PRNewswire/ -- Oxford BioTherapeutics and Berlin Chemi... See more »
October 2, 2014PR NEWSWIRE

Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance

OXFORD, England and BERLIN, October 2, 2014 /PRNewswire/ -- Oxford BioTherapeutics (OBT) and Berlin C... See more »

Social Media

Headquarters

94a Innovation Drive Milton Park

Abingdon, EnglandOX14 4RZ

44-1235-861-770

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. OBT was founded in 2003. OBT's headquarters is located in Abingdon, England, GB OX14 4RZ. It has raised 22.6M in 3 rounds. The la...

CEO

OBT's Founder & CEO, Christian Rohlff, currently has an approval rating of 86%. OBT's primary competitors are CytomX, ADC Therapeutics & ADC BIO.

Website

oxfordbiotherapeutics.com

Frequently Asked Questions about OBT

  1. When was OBT founded?

    OBT was founded in 2003
  2. Who is OBT's CEO?

    OBT's CEO is Christian Rohlff
  3. How much revenue does OBT generate?

    OBT generates $4.5M in revenue
  4. How much funding does OBT have?

    OBT has historically raised $22.6M in funding
  1. Where is OBT's headquarters?

    OBT's headquarters is in Abingdon England, GB
  2. How many employees does OBT have?

    OBT has 30 employees
  3. What sector does OBT operate in?

    OBT is in Biotechnology
  4. Who are OBT's competitors?

    OBT's top competitors are CytomX, ADC Therapeutics, ADC BIO